ALK-Mutated Non-Small-Cell Lung Cancer: A New Strategy for Cancer Treatment
- 15 May 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Lung
- Vol. 190 (4), 381-388
- https://doi.org/10.1007/s00408-012-9391-y
Abstract
The anaplastic lymphoma kinase (ALK) tyrosine kinase (TK) receptor has emerged recently as a potentially relevant biomarker and therapeutic target in solid and hematologic tumors. A variety of alterations in the ALK gene, such as mutations, overexpression, amplification, translocations, or other structural rearrangements, have been implicated in human cancer tumorigenesis. In this article we review the potential role that ALK may have in lung tumor origin, the methodology to detect the different molecular alterations, and the most important clinical aspects of ALK alterations in NSCLC patients.Keywords
This publication has 48 references indexed in Scilit:
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisThe Lancet Oncology, 2011
- Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung CancerJournal of Thoracic Oncology, 2011
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Anaplastic lymphoma kinase: signalling in development and diseaseBiochemical Journal, 2009
- Somatic and germline activating mutations of the ALK kinase receptor in neuroblastomaNature, 2008
- Identification of ALK as a major familial neuroblastoma predisposition geneNature, 2008
- EML4–ALK fusion transcript is not found in gastrointestinal and breast cancersBritish Journal of Cancer, 2008
- Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALKProceedings of the National Academy of Sciences of the United States of America, 2007
- Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3Proceedings of the National Academy of Sciences of the United States of America, 2006
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005